Display options
Cite
Okazaki Y, Kono I, Kuriki T, et al. Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats. J Clin Biochem Nutr. 2012;51(2):84-90doi: 10.3164/jcbn.11-100.
Okazaki, Y., Kono, I., Kuriki, T., Funahashi, S., Fushimi, S., Iqbal, M., Okada, S., & Toyokuni, S. (2012). Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats. Journal of clinical biochemistry and nutrition, 51(2), 84-90. https://doi.org/10.3164/jcbn.11-100
Okazaki, Yasumasa, et al. "Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats." Journal of clinical biochemistry and nutrition vol. 51,2 (2012): 84-90. doi: https://doi.org/10.3164/jcbn.11-100
Okazaki Y, Kono I, Kuriki T, Funahashi S, Fushimi S, Iqbal M, Okada S, Toyokuni S. Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats. J Clin Biochem Nutr. 2012 Sep;51(2):84-90. doi: 10.3164/jcbn.11-100. Epub 2012 Aug 04. PMID: 22962523; PMCID: PMC3432831.
Copy Download .nbib Format: NLM
Share it on

J Clin Biochem Nutr. 2012 Sep;51(2):84-90. doi: 10.3164/jcbn.11-100. Epub 2012 Aug 04.

Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats.

Journal of clinical biochemistry and nutrition

Yasumasa Okazaki, Isato Kono, Takayoshi Kuriki, Satomi Funahashi, Soichiro Fushimi, Mohammad Iqbal, Shigeru Okada, Shinya Toyokuni

Affiliations

  1. Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Showa-Ku, Nagoya, Aichi 466-8550, Japan.

PMID: 22962523 PMCID: PMC3432831 DOI: 10.3164/jcbn.11-100

Abstract

Milk provides a well-balanced source of amino acids and other ingredients. One of the functional ingredients in milk is lactoferrin (LF). LF presents a wide variety of bioactivities and functions as a radical scavenger in models using iron-ascorbate complexes and asbestos. Human clinical trials of oral LF administration for the prevention of colon polyps have been successful and demonstrated that dietary compounds exhibit direct interactions. However, antioxidative properties of LF in distant organs require further investigation. To study the antioxidant property of LF, we employed bovine lactoferrin (bLF) using the rat model of ferric nitrilotriacetate (Fe-NTA)-induced renal tubular oxidative injury. We fed rats with bLF (0.05%, w/w) in basal chow for 4 weeks and sacrificed them after Fe-NTA treatment. After intraperitoneal administration of 9.0 mg iron/kg Fe-NTA for 4 and 24 h, bLF pretreatment suppressed elevation of serum creatinine and blood urea nitrogen levels. In addition, we observed protective effects against renal oxidative tubular damage and maintenance of antioxidant enzyme activities in the bLF-pretreated group. We thus demonstrated the antioxidative effect of bLF against Fe-NTA-induced renal oxidative injury. These results suggest that LF intake is useful for the prevention of renal tubular oxidative damage mediated by iron.

Keywords: chemoprevention; ferric nitrilotriacetate; glutathione metabolism; lactoferrin; oxidative renal damage

References

  1. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2616-20 - PubMed
  2. J Toxicol Sci. 2009 Apr;34(2):163-74 - PubMed
  3. Mol Cell Biol. 2003 Jan;23(1):178-85 - PubMed
  4. Food Chem Toxicol. 2000 Jun;38(6):503-12 - PubMed
  5. Biosci Biotechnol Biochem. 2004 Apr;68(4):853-60 - PubMed
  6. Arch Biochem Biophys. 1989 Nov 1;274(2):348-54 - PubMed
  7. Antioxid Redox Signal. 2008 Feb;10(2):371-7 - PubMed
  8. J Clin Biochem Nutr. 2010 Nov;47(3):198-207 - PubMed
  9. Biometals. 2010 Jun;23(3):399-409 - PubMed
  10. Cancer Res. 1984 Nov;44(11):5086-91 - PubMed
  11. Cancer Res. 1997 Jun 15;57(12):2410-4 - PubMed
  12. FEBS Lett. 1995 Feb 13;359(2-3):189-91 - PubMed
  13. J Clin Invest. 2010 Jan;120(1):331-42 - PubMed
  14. Am J Pathol. 2002 Feb;160(2):419-24 - PubMed
  15. Lab Invest. 1997 Aug;77(2):145-55 - PubMed
  16. Eur J Biochem. 1984 Dec 17;145(3):659-76 - PubMed
  17. Haematologica. 1995 May-Jun;80(3):252-67 - PubMed
  18. Cancer Lett. 2007 Feb 8;246(1-2):41-6 - PubMed
  19. Biochim Biophys Acta. 1972 Feb 29;257(2):314-23 - PubMed
  20. Biochim Biophys Acta. 2005 Jun 10;1740(3):357-66 - PubMed
  21. Arch Biochem Biophys. 1994 Dec;315(2):219-25 - PubMed
  22. Anal Biochem. 1999 Sep 10;273(2):212-20 - PubMed
  23. Pathol Int. 1999 Feb;49(2):91-102 - PubMed
  24. Oncogene. 2004 May 13;23(22):3980-9 - PubMed
  25. Cancer. 2008 Jul 1;113(1):72-7 - PubMed
  26. Am J Pathol. 1979 Jun;95(3):663-73 - PubMed
  27. Lab Invest. 1997 Mar;76(3):365-74 - PubMed
  28. Free Radic Biol Med. 1997;22(6):1019-27 - PubMed
  29. Br J Nutr. 1998 Aug;80 Suppl 1:S77-112 - PubMed
  30. Free Radic Biol Med. 2003 Jun 1;34(11):1426-34 - PubMed
  31. Am J Physiol. 1998 Mar;274(3):L396-403 - PubMed
  32. Am J Pathol. 2007 Dec;171(6):1978-88 - PubMed
  33. Biometals. 2003 Mar;16(1):99-101 - PubMed
  34. Med Chem. 2011 May;7(3):224-30 - PubMed
  35. J Biol Chem. 1975 Jul 25;250(14):5475-80 - PubMed
  36. Oncogene. 1999 Jun 24;18(25):3793-7 - PubMed
  37. Am J Clin Nutr. 2003 Jun;77(6):1537S-1543S - PubMed
  38. Carcinogenesis. 2009 Jan;30(1):158-64 - PubMed
  39. Arch Biochem Biophys. 1995 Mar 10;317(2):405-11 - PubMed
  40. Br J Nutr. 2004 Apr;91(4):533-8 - PubMed
  41. Hepatol Res. 2006 Sep;36(1):27-32 - PubMed
  42. J Hepatol. 2008 Mar;48(3):486-93 - PubMed
  43. Toxicol Appl Pharmacol. 1985 Feb;77(2):267-74 - PubMed
  44. Jpn J Cancer Res. 1993 Jun;84(6):649-55 - PubMed
  45. Mol Med Rep. 2011 Sep-Oct;4(5):913-8 - PubMed
  46. Pediatr Res. 2002 Dec;52(6):964-72 - PubMed
  47. Free Radic Res. 2011 Aug;45(8):906-17 - PubMed

Publication Types